Evra Health
An AI health companion that turns your labs, wearables, and health history into simple daily actions.
Website: https://evrahealth.com/
Cover Block
PUBLIC
| Name | Evra Health |
| Tagline | An AI health companion that turns your labs, wearables, and health history into simple daily actions. [evrahealth.com, retrieved 2024] |
| Headquarters | Washington, US [evrahealth.com, retrieved 2024] |
| Founded | 2024 [evrahealth.com, retrieved 2024] |
| Stage | Pre-Seed |
| Business Model | Direct-to-Consumer (DTC) |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Global / Remote-First |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Pre-Seed (total disclosed ~$1,000,000) [Perplexity Sonar Pro Brief, retrieved 2026] |
Links
PUBLIC
- Website: https://evrahealth.com/
- LinkedIn: https://www.linkedin.com/company/evra-health
Data Accuracy: GREEN -- Confirmed by direct access to the company website and its LinkedIn profile.
Executive Summary
PUBLIC Evra Health is an early-stage AI-native health companion that aims to translate fragmented personal health data into a structured, daily regimen for chronic disease prevention, a proposition that warrants attention for its attempt to automate integrative medicine at a consumer scale. Founded in 2024 by physician and epidemiologist Dr. Amitha Kalaichandran, the company launched its waitlist in April, positioning itself as a direct-to-consumer platform that synthesizes lab results, wearable data, and health history into personalized action steps [Evra Health, retrieved 2024]. The founding wedge is a combination of clinical rigor and lifestyle-focused guidance, seeking to fill the gap between episodic medical visits with continuous, AI-driven support for conditions ranging from diabetes and hypertension to Long COVID and general wellness [Perplexity Sonar Pro Brief, retrieved 2024].
Dr. Kalaichandran brings a relevant, multi-disciplinary background to the venture, including medical training, a master's in health science, board certification in public health, and fellowship training in integrative medicine, which directly informs the product's therapeutic approach [Dr. Amitha, retrieved 2026]. The company's initial capitalization is a reported $1 million pre-seed round, though the investor syndicate remains undisclosed, funding a business model that is currently oriented toward individual subscribers rather than enterprise contracts [Perplexity Sonar Pro Brief, retrieved 2026]. Over the coming 12-18 months, the critical watch points will be the transition from waitlist to a publicly available product, the publication of any early user outcomes or clinical validation, and the company's ability to articulate a clear path to scaling its consumer acquisition in a crowded digital health market.
Data Accuracy: YELLOW -- Core product description and founder background are well-sourced; funding details are from a single aggregated report.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | Direct-to-Consumer (DTC) |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Global / Remote-First |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | Pre-Seed (total disclosed ~$1,000,000) |
Company Overview
PUBLIC
Evra Health was founded in 2024, launching its waitlist in April of that year, according to founder announcements [Dr. Amitha, 2026]. The company is headquartered in Washington, US, and operates a remote-first model, targeting a global consumer audience with an initial focus on the United States and India [Perplexity Sonar Pro Brief, 2024]. The entity is structured as a direct-to-consumer (DTC) business, a positioning reflected in its public messaging and waitlist sign-up flow.
The founding narrative centers on Dr. Amitha Kalaichandran, a physician, epidemiologist, and author, who frames the company's mission as a response to the reactive, fragmented, and overwhelming nature of modern healthcare [About - Evra Health, 2026]. The company's public milestones to date are limited to its founding, the launch of its waitlist, and the closing of a pre-seed financing round. A $1 million pre-seed round was reported in 2024, though the lead investor was not disclosed [Perplexity Sonar Pro Brief, retrieved 2026]. No subsequent funding announcements, major partnership deals, or significant customer deployment milestones have been covered by major news outlets.
Data Accuracy: YELLOW - Company details and founder background are confirmed via primary sources; the $1M pre-seed figure is reported from a single source.
Product and Technology
MIXED
Evra Health presents as an AI-native platform designed to function as a continuous health companion, translating disparate personal health data into a structured plan for chronic disease management. The core proposition is to ingest a user's lab results, wearable device streams, and self-reported health history, then output what the company calls "simple daily actions" grounded in integrative and lifestyle medicine [Perplexity Sonar Pro Brief, retrieved 2024]. This positions the product not as a diagnostic tool, but as a bridge between traditional, episodic clinical visits, aiming to close what the company describes as a "reactive, fragmented, and overwhelming" gap in modern care [Evra Health, retrieved 2024].
The platform's intended scope is broad, targeting over a dozen specific chronic conditions including hypertension, diabetes, obesity, autoimmune disorders like lupus and rheumatoid arthritis, and post-viral syndromes such as Long COVID and ME/CFS [Evra Health, retrieved 2024]. Its go-to-market is direct-to-consumer, with a waitlist launched in April 2026 and availability highlighted for the U.S., India, and global users [Evra Health Launches in April for Personalized Preventive..., 2026] [Perplexity Sonar Pro Brief, retrieved 2024]. From a technology standpoint, the public description emphasizes the combination of clinical guidelines with real-world data, though the specific AI models, data integration architecture, and security protocols are not detailed. The team page references roles in compliance, data governance, and prompt engineering, which suggests a stack involving large language models and structured health data pipelines [Evra Health, retrieved 2024].
Data Accuracy: YELLOW -- Product claims are consistent across the company's owned channels and founder communications, but technical implementation details and independent validation of the AI's outputs are not publicly available.
Market Research
PUBLIC
The market for AI-driven chronic disease management is coalescing around a clear need, as traditional healthcare systems struggle to provide continuous, personalized support for the growing burden of long-term conditions.
A precise total addressable market (TAM) for AI-native health companions is not yet established in third-party reports. However, the underlying conditions Evra targets represent massive and expanding categories. The global digital health market, a relevant proxy, was valued at approximately $211 billion in 2022 and is projected to reach $809 billion by 2030, growing at a compound annual rate of 18.6% [Grand View Research, 2023]. Within this, chronic disease management applications constitute a significant segment, driven by the rising prevalence of conditions like diabetes, hypertension, and obesity.
Several demand drivers underpin this growth. The shift toward value-based care and preventive health creates economic incentives for interventions that manage population health outside clinical settings. Consumer adoption of wearable devices has created a new stream of real-world health data, estimated at over 1 billion connected devices globally [IDC, 2023], which can be leveraged for personalized insights. Furthermore, persistent gaps in care access and clinician burnout have intensified the search for scalable solutions that extend care continuity between visits.
Adjacent and substitute markets include traditional disease management programs offered by health plans, standalone wellness apps, and telehealth platforms. The key differentiator for Evra's proposed category is the integration of clinical guidelines with integrative medicine and the automated translation of multi-source data into daily action plans, a step beyond generic tracking or episodic virtual consultations.
Regulatory and macro forces present both tailwinds and headwinds. The U.S. Food and Drug Administration's evolving framework for Software as a Medical Device (SaMD) and digital therapeutics provides a potential pathway for validation but also introduces compliance complexity. Data privacy regulations, including HIPAA in the U.S. and GDPR internationally, are non-negotiable foundational requirements. Macro trends like aging populations and the rising economic cost of chronic disease, estimated to account for over 85% of U.S. healthcare spending [CDC, 2022], create a powerful tailwind for solutions that demonstrably improve outcomes and reduce costs.
Digital Health Market 2022 | 211 | $B
Digital Health Market 2030 (projected) | 809 | $B
The projected growth of the broader digital health market illustrates the capital and strategic attention flowing into the sector, though it does not directly validate Evra's specific wedge. The scale of the opportunity is clear, but success will depend on capturing a defined segment within this expansive landscape.
Data Accuracy: YELLOW -- Market sizing from a single third-party report; demand drivers and regulatory context are widely reported but not specifically tied to the company's model.
Competitive Landscape
MIXED
Evra Health enters a market defined by a crowded field of digital health applications, but positions itself at a specific intersection of AI-driven personalization, integrative medicine, and direct-to-consumer chronic disease management.
The competitive map can be segmented into three broad categories. First, broad wellness and fitness platforms like Fitbit (Google) and Apple Health offer data aggregation and basic health insights but are not designed for clinical-grade chronic disease management or to integrate with a user's full medical history [Apple, 2024]. Second, condition-specific digital therapeutics and management apps such as Omada Health (for diabetes and hypertension) and Livongo (now part of Teladoc) provide structured, often employer-sponsored, programs but typically focus on single conditions and operate within a more traditional, episodic care model [Teladoc, 2024]. Third, a growing set of AI-powered health assistants and clinical decision support tools aimed at providers, like those from Babylon Health or Ada Health, which prioritize symptom checking and triage rather than longitudinal, lifestyle-focused action planning for chronic conditions [Ada Health, 2024].
Evra's current defensible edge rests primarily on its founder's specific clinical and public health expertise, which informs its integrative medicine approach. Dr. Amitha Kalaichandran's background in epidemiology, pediatrics, and integrative medicine training provides a foundation for the platform's clinical guidelines that larger tech companies may lack the nuanced focus to develop [Dr. Amitha, 2026]. Furthermore, its positioning as an "AI-native" companion built from the ground up to synthesize labs, wearables, and history into daily actions is a product architecture claim that differentiates it from legacy platforms that have bolted AI features onto existing apps. This edge is perishable, however, as it relies on continued first-mover execution in a narrow niche before well-capitalized incumbents decide to build or acquire similar functionality.
The company is most exposed on two fronts. Distribution and scale present a significant challenge; Evra's direct-to-consumer model requires substantial marketing spend and user acquisition prowess to compete with the built-in user bases of device makers (Apple, Google) and employer-sponsored programs (Omada, Livongo). Without a clear B2B2C or provider partnership channel, scaling will be capital-intensive. Secondly, regulatory and clinical validation is a high barrier. While Evra's focus is on lifestyle and prevention, operating in the chronic disease management space adjacent to regulated digital therapeutics invites scrutiny. Competitors with existing FDA clearances or large-scale clinical studies, like Omada, have a formidable moat that a pre-seed startup cannot quickly replicate [Business Wire, 2023].
The most plausible 18-month scenario hinges on Evra's ability to secure a strategic partnership or niche dominance. If the company can demonstrate early user engagement and outcomes data (even n-of-1 or pilot study level), it could become an attractive acquisition target for a larger digital health platform seeking to deepen its integrative medicine offerings,a winner if it proves product-market fit in a specific sub-segment like women's midlife health or Long COVID management. Conversely, if user growth stalls and the company fails to transition from a waitlist to a monetized, engaged user base, it risks being outflanked by a well-funded incumbent that simply adds a "daily action planner" module to its existing app, rendering Evra's wedge less distinctive.
Data Accuracy: YELLOW -- Competitive analysis is based on public positioning of named companies; direct competitive intelligence on Evra's market share or head-to-head win/loss data is not available.
Opportunity
PUBLIC The prize for Evra Health is a redefinition of the patient journey for chronic disease management, moving from reactive, episodic care to a continuous, AI-guided partnership that could scale to serve millions globally.
The headline opportunity is the creation of a category-defining, AI-native health companion that becomes the default operating system for personal health management. This outcome is reachable because the company is targeting a fundamental and persistent gap in the healthcare system: the lack of continuous, personalized support between clinical visits for managing long-term conditions [Evra Health, retrieved 2024]. The founder's clinical and public health background provides a credible foundation for translating complex medical guidelines into daily actions, a task that has eluded many pure-play tech solutions. If Evra can successfully integrate diverse data streams (labs, wearables, patient history) and deliver trusted, actionable insights, it could establish a new standard of care for the estimated hundreds of millions of people globally living with one or more chronic conditions.
Growth could follow several distinct, high-conviction paths, each with identifiable catalysts.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Direct-to-Consumer Premium Subscription | Evra scales as a global, direct-to-patient subscription service, monetizing personalized health guidance as a wellness and chronic disease management tool. | A successful, data-driven pilot in the U.S. and India demonstrating improved user outcomes and retention [Evra Health, retrieved 2024]. | The DTC model bypasses slow enterprise sales cycles. The founder's public writing and media presence provides a built-in channel for early user acquisition and trust-building [The New York Times, 2020]. |
| B2B2C Payer/Employer Partnership | Evra is white-labeled or integrated as a value-based care tool for health plans and self-insured employers seeking to reduce long-term costs of chronic conditions. | Securing a pilot partnership with a regional health plan or a large, forward-thinking employer. | The company's website already includes a page targeting employers and health plans, indicating this is a considered channel [evrahealth.com, retrieved 2024]. The focus on quantifiable risk reduction aligns directly with payer incentives. |
Compounding for Evra would manifest as a deepening data moat and a strengthening trust brand. Each user interaction generates proprietary data on how specific interventions (diet, sleep, activity) correlate with biomarker changes across diverse populations and conditions. This dataset, unique in its combination of clinical and lifestyle data, could continuously refine the AI's recommendations, creating a feedback loop where better outcomes attract more users, which in turn generates more data for better models [Evra Health, retrieved 2024]. Early signs of this flywheel are not yet publicly visible in the form of published outcomes or scaled user bases, but the product architecture is explicitly designed to create this "continuous loop between data, intelligence, and action" [About - Evra Health, retrieved 2026].
The size of the win is anchored by the valuation of digital health companies that have successfully aggregated engaged patient populations. For a scenario where Evra captures a meaningful share of the direct-to-consumer integrative health market, a relevant comparable is Teladoc Health's Livongo acquisition, which valued a digital chronic condition management platform at approximately $18.5 billion in 2020. While Evra is at a pre-seed stage, a plausible, scaled outcome in the DTC or B2B2C channel could see the company valued as a platform managing millions in annual recurring revenue for a high-margin software service (scenario, not a forecast). The total addressable market is the global spend on chronic disease management, which runs into the trillions annually, suggesting even a single-digit percentage penetration represents a multi-billion dollar opportunity.
Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated vision and target markets, which are publicly documented. The growth scenarios are plausible extrapolations from these materials, but lack external validation from executed partnerships or user traction data.
Sources
PUBLIC
[evrahealth.com, retrieved 2024] Evra Health | https://evrahealth.com/
[Perplexity Sonar Pro Brief, retrieved 2024] Perplexity Sonar Pro Brief on Evra Health | https://www.perplexity.ai/
[Dr. Amitha, retrieved 2026] Dr. Amitha | https://dramitha.com/
[About - Evra Health, retrieved 2026] About - Evra Health | https://evrahealth.com/about/
[Evra Health Launches in April for Personalized Preventive..., 2026] Evra Health Launches in April for Personalized Preventive Health | https://evrahealth.com/
[The New York Times, 2020] Opinion | How Can We Bear This Much Loss? | https://www.nytimes.com/2020/09/23/opinion/grief-covid-book-of-job.html
[Grand View Research, 2023] Digital Health Market Size Report, 2023-2030 | https://www.grandviewresearch.com/industry-analysis/digital-health-market
[IDC, 2023] Worldwide Wearables Market Forecast, 2023 | https://www.idc.com/
[CDC, 2022] Chronic Diseases in America | https://www.cdc.gov/chronicdisease/index.htm
[Apple, 2024] Apple Health | https://www.apple.com/ios/health/
[Teladoc, 2024] Teladoc Health | https://www.teladochealth.com/
[Ada Health, 2024] Ada Health | https://ada.com/
[Business Wire, 2023] Omada Health Announces New Clinical Data | https://www.businesswire.com/news/home/20230523005321/en/
[Perplexity Sonar Pro Brief, retrieved 2026] Funding Information for Evra Health | https://www.perplexity.ai/
Articles about Evra Health
- Evra Health's AI Companion Translates Lab Results Into Daily Actions — A physician-founded startup uses a $1 million pre-seed round to build a direct-to-consumer platform for chronic disease prevention.